Concourse Capital Focused Equity ETF (CCFE)

On our desk, we are seeing a stark divergence between CCFE's concentrated small-value mandate and its actual execution. With a portfolio P/E sitting at 16.05x against a category average of 13.50x, the valuation premium is difficult to justify given that its 1-year trailing return of roughly +5.9% severely lags the Morningstar category median of +28.8%. Investors are simply paying more and getting less.

When evaluating CCFE's active methodology for potential deployment, our quantitative team highlighted its heavy 48% skew toward the Industrials sector. In mid-2026, this creates acute vulnerability to direct tariff pressures and global-trade friction. While the sub-adviser focuses on companies undergoing transitional catalysts like deleveraging or mergers, the macroeconomic headwinds outweigh the idiosyncratic alpha potential right now.

From a risk management standpoint, CCFE scores a 94, placing it squarely in the top decile of risk for all funds. Its 1-year beta of 1.17 demonstrates above-average market sensitivity, but this is paired with a dismal Sharpe ratio of 0.19. The fund dropped nearly 19.5% from its all-time high of $31.91 reached in February 2026, dropping noticeably harder than the broader Small Value category peak drawdowns.

Looking at the technical indicators across our charting software, CCFE is struggling below all major moving averages. With a price around $25.79 sitting beneath the MA50 ($28.26), MA150 ($27.52), and MA200 ($27.03), the momentum is decidedly bearish. Furthermore, its 1-year trailing return places it in the 100th percentile—effectively the worst—of its peer group.

Analyzing CCFE's structural profile, its expense ratio of 0.95% is notably steep for a $37.2M AUM fund, especially considering it tracks no underlying index and relies purely on active management. Combined with a meager indicated dividend yield of 0.02% and negative return-vs-category rankings across 3Y, 5Y, and 10Y horizons, the cost-to-performance ratio fails our fundamental screening criteria.